Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Percheron Therapeutics ( (AU:PER) ) has shared an announcement.
Percheron Therapeutics has alerted its shareholders about unauthorized correspondence from Powerhouse Ventures Limited, which included a pre-filled proxy form for an upcoming General Meeting. The company emphasized that these proxy forms, if not submitted directly to the company’s share registry, may be invalid, and urged shareholders to follow proper procedures to ensure their votes are counted.
More about Percheron Therapeutics
Percheron Therapeutics Limited is a publicly listed biotechnology company focused on developing and commercializing novel therapies for rare diseases. Its lead program, avicursen (ATL1102), targets the CD49d receptor and has been investigated for inflammatory conditions like multiple sclerosis and Duchenne muscular dystrophy.
Technical Sentiment Signal: Sell
Current Market Cap: $8.34M
For an in-depth examination of PER stock, go to TipRanks’ Stock Analysis page.